American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

American Head & Neck Society | AHNS


The mission of the AHNS is to advance Education, Research, and Quality of Care for the head and neck oncology patient.

  • About
    • Mission Statement and Purpose
    • Divisions & Services of the Society
      • Education
        • Scientific Program/Resident Courses
        • Surgical Videos
        • Journal Club
        • Journals
        • Global Outreach
        • Awards
          • Margaret F. Butler Award
      • Diversity, Equity and Inclusion Division
      • Patient Care
        • Cancer Survivorship
          • Patient Education on Post-Treatment Care
          • Interviews with Cancer Survivors
        • Cancer Prevention
          • SLIDE DECK: HPV-Related Oropharyngeal Cancer
        • Guidelines/Position Statements
        • Find-A-Physician
      • Research
        • Grant Information
        • Clinical Trial
        • Tissue Banks
      • Administrative Divison
        • Development Service Process for Evaluating Projects Requiring Funding
    • Leadership
    • History
      • Society Background
      • AHNS History Interviews
      • Past Presidents
      • In Memory
    • AHNS Newsletter
    • Professionalism & Ethics
    • AHNS Policies and Procedures (P&P) Manual
    • AHNS Foundation
    • AHNS Bylaws
    • AHNS Staff
    • AHNS News and Announcements
    • COVID-19 Bulletin Board
  • Heads Up!
  • Post a Job
  • Meetings
    • AHNS Virtual Education Series
      • TORS Webinar Series
    • AHNS Meetings Info
    • AHNS Call For Abstracts
    • AHNS Call For Late Breaking Abstracts
    • Exhibitor and Support Opportunities
    • Past Meetings
    • Related Meetings
  • For Patients
  • For Trainees
    • Accredited Fellowships
      • Fellowship Match
      • Directory of Fellowships
      • Fellowship Curriculum
      • Certificate of Completion Request
      • Fellowship Graduates
      • For Program Directors
      • For Current AHNS Fellows
    • AHNS Surgical Videos
    • Fellows’ Virtual Tumor Boards
    • Cutaneous Cancer
  • Sections
    • Endocrine Surgery
    • Skull Base Surgery Section
    • Reconstructive Head & Neck Surgery
    • Mucosal Malignancy Section
      • Mucosal Malignancy Section Patient Information
    • Salivary Gland
    • Cutaneous Cancer
  • Member Central
    • Join AHNS
    • Find-A-Physician
    • Mailing List Order
  • Log In
  • Donate

Published on April 17, 2020 by Joseph Goodman

AHNS Basic Science/Translational Newsletter Vol 1

Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer

Sadeghi N, Khalife S, Mascarella MA, Ramanakumar AV, Richardson K, Joshi AS, Bouganim N, Taheri R, Fuson A, Siegel R.

From Head and Neck, March 2020;42(3):417-425.

Article Review by Joe Goodman, MD

Background / Hypothesis
According to the authors, a paradigm shift is underway leading to de-escalation trials for HPV-associated oropharynx cancer (OPC). Because of the excellent prognosis for most HPV OPC, efforts have been made to improve quality-of-life after treatment and reduce treatment-related morbidity. While most de-escalation trials have looked at reducing radiation dose or eliminating chemotherapy, this trial uses neoadjuvant chemo therapy plus transoral surgery (NAC+S) with the goal of avoiding post-op radiation based on surgical pathology.

Design
This is a prospective cohort of patients with p16+ OPC (stage III/IV AJCC 7th) treated with chemotherapy consisting of 3 cycles of cisplatin/docetaxel every 3 weeks followed by transoral surgery and neck dissection. N3 disease was excluded. All 54 patients demonstrated at least partial response to the chemotherapy regimen based on preoperative post-treatment imaging. Goal was to correlate reduction in tumor volume with likelihood of complete pathologic response pCR. Surgical pathology was assessed for presence of primary tumor and neck metastases to determine yTNM restaging and assess need for postoperative XRT. Partial response was defined as any residual tumor. MRI response of tumor was also correlated with pathological response, but not RECIST criteria because often pathological response was underpredicted by imaging response.

Summary of Results
Surgical pathology showed overall pCR of 44%, with 72% pCR at the primary and 57% pCR in the neck.

96% had negative margins. There were 3 mortalities. Preop imaging volume reduction of 90% or greater had predictive value for pCR (sensitivity 0.82 and specificity 0.73). More patients at all stages showed pCR than PR on surgical pathology although this was not specifically analyzed.

Strengths

  • Building on several other small series to show efficacy of neoadjuvant chemotherapy regimen based on surgical pathology, justifying de-escalation strategies
  • Since transoral robotic surgery involves en bloc resections of radical tonsil or base of tongue, as well as neck dissection, less likelihood of missing a small discontiguous positive margin vs endoscopic partial resection

 Weaknesses

  • Mortality of 5.6% seems high, not well explained if they declined recommended post-op treatment
  • Survival outcomes not analyzed but this data is forthcoming
  • No real attempt at understanding cellular mechanisms for this phenomenon
  • Not powered to analyze based on smoking status as possible contributor to biological response in p16+ OPC
  • While toxicity seems acceptable, long-term studies will need to be done

Key Points

  • There seems significant biological response of p16+ OPC to this particular neoadjuvant chemotherapy regimen of cisplatin and taxotere. Other regimens have been studied, for instance the Weiss article from UNC, as well as bioselection papers from UM for larynx cancer.
  • Even the original VA study showed 30% CR.
  • While the current treatment paradigm states that chemotherapy is never sufficient for primary treatment of squamous cell carcinoma, in many cases in this series there was no evidence of tumor at the primary site or in the neck as assessed on surgical pathology. This speaks to the possible for bioselection strategies using NAC+S for de-escalation in p16+ OPC.
  • Also supports an increased role for transoral surgery with good functional outcomes after neoadjuvant chemotherapy, avoiding “triple-therapy”—unless dictated by adverse features on surgical pathology – Supports role of post-chemotherapy pre-operative imaging to predict likelihood of pathologic complete response to further refine the treatment algorithm
  • Long term, multi-institutional studies of disease free survival and toxicity will need to be done

From the Basic Science/Translational Section
Jeffrey C. Liu MD Vice Chair
Richard Wong Md Chair

  • Bio
  • Latest Posts
Joseph Goodman

Joseph Goodman

Dr. Goodman is currently Assistant Professor of Otolaryngology and Associate Residency Program Director at The George Washington University in Washington, DC. He serves as a member of the Basic and Translational Science Service of the AHNS and is a working group member of the Salivary Gland Section. His research interests include HPV-related oropharyngeal cancer and reconstructive surgery of the Head and Neck.
Joseph Goodman

Latest posts by Joseph Goodman (see all)

  • AHNS Basic Science/Translational Newsletter Vol 1 - April 17, 2020
Views: 0

Share:

  • Facebook
  • Twitter
  • LinkedIn

Related

Subscribe to Heads Up!

Enter your email address to subscribe to Heads Up! and receive notifications of new posts by email.

Join 205 other subscribers

AHNS Meetings

WEBINAR CALENDAR

AHNS Call For Abstracts

News and Announcements

  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – Final Day To Submit Abstracts March 22, 2023
  • ARS NASBS AHNS Sinonasal Cancer Collaborative – Sinonasal Malignancy Virtual Tumor Board March 20, 2023
  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts March 16, 2023
  • Registration for the AHNS 2023 is now open! March 10, 2023
  • What’s New on the AHNS Website March 9, 2023

AHNS on Facebook

AHNS on Facebook

Contact Us

AHNS, 11300 W. Olympic Blvd, Suite 600
Los Angeles, CA 90064
ph: (310) 437-0559 / fx: (310) 437-0585
[email protected]

Search this website

Follow the AHNS

  • Email
  • Facebook
  • Twitter
  • YouTube

Recent Heads Up! Posts

AHNS 2023 Meeting – Late Breaking Call For Abstracts – Final Day To Submit Abstracts

ARS NASBS AHNS Sinonasal Cancer Collaborative – Sinonasal Malignancy Virtual Tumor Board

AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts

More News and Announcements

© 2002–2023 American Head and Neck Society · Privacy and Return Policy
· Managed by BSC Management, Inc